Endologix (ELGX) Given Daily News Sentiment Score of 0.14

Media coverage about Endologix (NASDAQ:ELGX) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endologix earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 46.5289166748611 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ELGX opened at $4.21 on Wednesday. Endologix has a 12-month low of $3.75 and a 12-month high of $7.66. The stock has a market capitalization of $340.76, a price-to-earnings ratio of -8.77 and a beta of 0.32. The company has a current ratio of 2.36, a quick ratio of 1.62 and a debt-to-equity ratio of 2.77.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.13. The company had revenue of $44.00 million for the quarter, compared to the consensus estimate of $44.91 million. Endologix had a negative net margin of 36.65% and a negative return on equity of 44.91%. The company’s revenue for the quarter was down 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. equities analysts predict that Endologix will post -0.73 EPS for the current fiscal year.

Several brokerages have weighed in on ELGX. JPMorgan Chase lowered shares of Endologix from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. ValuEngine downgraded shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Oppenheimer set a $5.00 price target on shares of Endologix and gave the company a “hold” rating in a report on Thursday, February 22nd. Zacks Investment Research downgraded shares of Endologix from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Finally, BidaskClub downgraded shares of Endologix from a “hold” rating to a “sell” rating in a report on Friday, January 19th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $5.41.

WARNING: “Endologix (ELGX) Given Daily News Sentiment Score of 0.14” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2018/04/18/endologix-elgx-given-daily-news-sentiment-score-of-0-14.html.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply